DOCSLIB.ORG

Download Price-List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Price-List INTERNATIONAL PHARMA-GRADE Name Unit size Description Categories Price Aerius® 5 mg 20 tb. 20 x 5 mg tabs/pack DESLORATADINE (5 mg/tab) Allergy Treatment 15,40 USD Combivent® 250 mg 20 vial 20 x 2,5 ml nebulles/pack SALBUTAMOL (2.5 mg/2.5 ml), Allergy Treatment 25,00 USD IPRATROPIUM BROMIDE (0.5 mg/2.5 ml) Lacipil® 4 mg 28 tb. 28 x 4 mg tabs/pack LACIDIPINE (4 mg/tab) Allergy Treatment 21,00 USD Seretide® 100 mcg 60 dose diskus 1 x 60 dose disk/pack FLUTICASONE (100 mcg/dose), SALMETEROL (50 mcg/dose) Allergy Treatment 31,00 USD Seretide® 125 mcg 120 inh. 1 x 120 dose inhaler/pack FLUTICASONE (125 mcg/inh), SALMETEROL (50 mcg/inh) Allergy Treatment 27,50 USD Seretide® 250 mcg 60 dose diskus 1 x 60 dose disk/pack FLUTICASONE (250 mcg/dose), SALMETEROL (50 mcg/dose) Allergy Treatment 46,20 USD Seretide® 250 mg 120 inh. 1 x 120 dose inhaler/pack FLUTICASONE (250 mcg/inh), SALMETEROL (50 mcg/inh) Allergy Treatment 52,80 USD Seretide® 500 mcg 60 dose diskus 1 x 60 dose disk/pack FLUTICASONE (500 mcg/dose), SALMETEROL (50 mcg/dose) Allergy Treatment 70,00 USD Singulair® 10 mg 28 tb. 28 x 10 mg tabs/pack MONTELUKAST SODIUM (10 mg/tab) Allergy Treatment 13,50 USD Singulair® 4 mg 28 tb. 28 x 4 mg tabs/pack MONTELUKAST SODIUM (4 mg/tab) Allergy Treatment 15,70 USD Singulair® 5 mg 28 tb. 28 x 5 mg tabs/pack MONTELUKAST SODIUM (5 mg/tab) Allergy Treatment 21,00 USD Spiriva Respimat MTD® 2.5 mcg/30 dose 1 x 30 dose inhaler/pack TIOTROPIUM BROMIDE (2.5 mcg/tab) Allergy Treatment 46,20 USD Spiriva® 18 mcg 30 cap. 30 x 18 mcg tabs/pack TIOTROPIUM BROMIDE (18 mcg/tab) Allergy Treatment 50,00 USD Ventolin Inhaler® 100 mcg/200 dose 1 x 200 dose inhaler/pack ALBUTEROL (100 mcg/dose) Allergy Treatment 18,15 USD Ventolin Syrup® 150 ml 1 x 150 ml vial/pack ALBUTEROL (2 mg/5 ml) Allergy Treatment 13,75 USD Ventolin® 4 mg. 100 tb. 100 x 4 mg tabs/pack ALBUTEROL (4 mg/tab) Allergy Treatment 13,20 USD Zaditen® 1 mg 30 tb. 30 x 1 mg tabs/pack KETOTIFEN (1 mg/tab) Allergy Treatment 11,55 USD Zaditen® oral drops 25 ml 1 x 25 ml ampule/pack KETOTIFEN (1 mg/ml) Allergy Treatment 12,60 USD Brufen Retard® 800 mg 14 tb. 14 x 800 mg tabs/pack IBUPROFEN (800 mg/tab) Anti-inflammatory 14,00 USD Brufen® 400 mg 20 tb. 20 x 400 mg tabs/pack IBUPROFEN (400 mg/tab) Anti-inflammatory 8,25 USD Brufen® 600 mg 20 tb. 20 x 600 mg tabs/pack IBUPROFEN (600 mg/tab) Anti-inflammatory 10,50 USD Cataflam® 50 mg 20 tb. 20 x 50 mg tabs/pack DICLOFENAC POTASSIUM (50 mg/tab) Anti-inflammatory 8,25 USD Deltacortril® 5 mg 20 tb. 20 x 5 mg tabs/pack PREDNISOLONE (5 mg/tab) Anti-inflammatory 7,50 USD Precort® 16 mg 20 tb. 20 x 16 mg tabs/pack METHYLPREDNISOLONE (16 mg/tab) Anti-inflammatory 26,00 USD Precort® 4 mg 20 tb. 20 x 4 mg tabs/pack METHYLPREDNISOLONE (4 mg/tab) Anti-inflammatory 13,20 USD Champix® 0,5 mg 11 +1 mg 98 tb 11 x 0,5 mg + 98 x 1 mg tabs/pack VARENICLINE TARTARATE (0.5 mg/tab) Anti-Smoking 363,00 USD Champix® 0.5*11-1*42 tb. 11 x 0,5 mg + 42 x 1 mg tabs/pack VARENICLINE TARTARATE (0.5 mg/tab) Anti-Smoking 242,00 USD Champix® 1 mg 56 tb. 56 x 1 mg tabs/pack VARENICLINE TARTARATE (1 mg/tab) Anti-Smoking 170,00 USD Aldactone® 100 mg 16 tb. 16 x 100 mg tabs/pack SPIRONOLACTONE (100 mg/tab) Cardiovascular 7,90 USD Aldactone-A® 25 mg 20 tb. 20 x 25 mg tabs/pack SPIRONOLACTONE (25 mg/tab) Cardiovascular 5,70 USD Atacand Plus® 16/12.5 mg./28 tb. 28 x 16/12,5 mg tabs/pack CANDESARTAN CILEXETIL (16 mg/tab), Cardiovascular 27,50 USD HYDROCHLOROTHIAZIDE (12.5 mg/tab) Atacand Plus® 16/12.5 mg./84 tb. 84 x 16/12,5 mg tabs/pack CANDESARTAN CILEXETIL (16 mg/tab), Cardiovascular 55,00 USD HYDROCHLOROTHIAZIDE (12.5 mg/tab) Atacand® 16 mg 28 tb. 28 x 16 mg tabs/pack CANDESARTAN CILEXETIL (16 mg/tab) Cardiovascular 17,60 USD Atacand® 32 mg 28 tb. 28 x 32 mg tabs/pack CANDESARTAN CILEXETIL (32 mg/tab) Cardiovascular 22,55 USD Atacand® 8 mg 28 tb. 28 x 8 mg tabs/pack CANDESARTAN CILEXETIL (8 mg/tab) Cardiovascular 12,70 USD Ator® 10 mg 30 tb. 30 x 10 mg tabs/pack ATORVASTATIN (10 mg/tab) Cardiovascular 15,40 USD Ator® 20 mg 30 tb. 30 x 20 mg tabs/pack ATORVASTATIN (20 mg/tab) Cardiovascular 25,00 USD Ator® 40 mg 30 tb. 30 x 40 mg tabs/pack ATORVASTATIN (40 mg/tab) Cardiovascular 34,50 USD Ator® 80 mg 30 tb. 30 x 80 mg tabs/pack ATORVASTATIN (80 mg/tab) Cardiovascular 45,50 USD Beloc Zok® 100 mg 20 tb. 20 x 100 mg tabs/pack METOPROLOL TARTARATE (100 mg/tab) Cardiovascular 27,50 USD Beloc Zok® 25 mg 20 tb. 20 x 25 mg tabs/pack METOPROLOL TARTARATE (25 mg/tab) Cardiovascular 22,00 USD Beloc Zok® 50 mg 20 tb. 20 x 50 mg tabs/pack METOPROLOL TARTARATE (50 mg/tab) Cardiovascular 24,75 USD Brilinta® 60 mg. 56 tb. 56 x 60 mg tabs/pack TICAGRELOR (60 mg/tab) Cardiovascular 182,00 USD Brilinta® 90 mg. 56 tb. 56 x 90 mg tabs/pack TICAGRELOR (90 mg/tab) Cardiovascular 198,00 USD Cantab Plus® 16/12.5 mg./28 tb. 28 x 16/12,5 mg tabs/pack CANDESARTAN CILEXETIL, Cardiovascular 24,20 USD HYDROCHLOROTHIAZIDE (16 mg + 12.5 mg/tab) Cantab Plus® 32/12.5 / 28 tb. 28 x 32/12,5 mg tabs/pack CANDESARTAN CILEXETIL, Cardiovascular 27,50 USD HYDROCHLOROTHIAZIDE (32 mg + 12.5 mg/tab) Cantab® 16 mg 28 tb. 28 x 16 mg tabs/pack CANDESARTAN CILEXETIL, Cardiovascular 24,20 USD HYDROCHLOROTHIAZIDE (16 mg + 12.5 mg/tab) Cantab® 32 mg 28 tb. 28 x 32 mg tabs/pack CANDESARTAN CILEXETIL, Cardiovascular 27,50 USD HYDROCHLOROTHIAZIDE (32 mg + 12.5 mg/tab) Cantab® 8 mg 28 tb. 28 x 8 mg tabs/pack CANDESARTAN CILEXETIL (8 mg/tab) Cardiovascular 17,60 USD Cardura® 2 mg 20 tb. 20 x 2 mg tabs/pack DOXAZOSIN (2 mg/tab) Cardiovascular 10,00 USD Cardura® 4 mg 20 tb. 20 x 4 mg tabs/pack DOXAZOSIN (4 mg/tab) Cardiovascular 12,50 USD Clexane® 4000 10 x 0.4 ml.inj. 10 x 0,4 ml pen/pack ENOXAPARIN SODIUM (40 mg/0.4 ml) Cardiovascular 37,50 USD Clexane® 6000 2 x 0.6 ml inj. 2 x 0,6 ml pen/pack ENOXAPARIN SODIUM (60 mg/0.6 ml) Cardiovascular 38,50 USD Clexane® 8000 2 x 0.8 ml.inj. 2 x 0,8 ml pen/pack ENOXAPARIN SODIUM (80 mg/0.8 ml) Cardiovascular 37,50 USD Co-Diovan® 160/12.5 mg.28 tb. 28 x 160/12,5 mg tabs/pack HYDROCHLOROTHIAZIDE (12.5 mg/tab), Cardiovascular 38,50 USD VALSARTAN (160 mg/tab) Co-Diovan® 160/25 mg.28 tb. 28 x 160/25 mg tabs/pack HYDROCHLOROTHIAZIDE (25 mg/tab), Cardiovascular 30,80 USD VALSARTAN (160 mg/tab) Co-Diovan® 320/12.5 mg.28 tb. 28 x 320/12,5 mg tabs/pack HYDROCHLOROTHIAZIDE (12.5 mg/tab), Cardiovascular 38,50 USD VALSARTAN (320 mg/tab) Co-Diovan® 320/25 mg.28 tb. 28 x 320/25 mg tabs/pack HYDROCHLOROTHIAZIDE (25 mg/tab), Cardiovascular 36,30 USD VALSARTAN (320 mg/tab) Co-Diovan® 80/12.5 mg.28 tb. 28 x 80/12,5 mg tabs/pack HYDROCHLOROTHIAZIDE (12.5 mg/tab), Cardiovascular 19,80 USD VALSARTAN (80 mg/tab) Cordarone® 200 mg. 30 tb. 30 x 200 mg tabs/pack AMIODARONE (200 mg/tab) Cardiovascular 10,50 USD Coversyl® 10 mg 30 tb. 30 x 10 mg tabs/pack PERINDOPRIL ARGININE (10 mg/tab) Cardiovascular 16,50 USD Coversyl® 5 mg 30 tb. 30 x 5 mg tabs/pack PERINDOPRIL ARGININE (5 mg/tab) Cardiovascular 14,30 USD Cozaar® 50 mg 28 tb. 28 x 50 mg tabs/pack LOSARTAN (50 mg/tab) Cardiovascular 20,00 USD Crestor® 20 mg 28 tb. 28 x 20 mg tabs/pack ROSUVASTATIN (20 mg/tab) Cardiovascular 21,00 USD Daflon® 500 mg. 60 tb. 60 x 500 mg tabs/pack DIOSMINA (450 mg/tab), Cardiovascular 31,00 USD HESPERIDINA (50 mg/tab) Exforge® 10/160 mg 28 tb. 28 x 10/160 mg tabs/pack AMLODIPINE (10 mg/tab), Cardiovascular 20,00 USD VALSARTAN (160 mg/tab) Exforge® 5/160 mg 28 tb. 28 x 5/160 mg tabs/pack AMLODIPINE (5 mg/tab), Cardiovascular 19,00 USD VALSARTAN (160 mg/tab) Lasix® 40 mg 12 tb. 12 x 40 mg tabs/pack FUROSEMIDE (40 mg/tab) Cardiovascular 7,50 USD Lipitor® 10 mg 30 tb. 30 x 10 mg tabs/pack ATORVASTATIN (10 mg/tab) Cardiovascular 11,00 USD Lipitor® 20 mg 90 tb. 90 x 20 mg tabs/pack ATORVASTATIN (20 mg/tab) Cardiovascular 14,00 USD Lipitor® 40 mg 30 tb. 30 x 40 mg tabs/pack ATORVASTATIN (40 mg/tab) Cardiovascular 16,50 USD Micardis Plus® 80/12,5 mg 28 tb.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/7064 (2006.01) A61P 33/14 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 45/06 (2006.01) A61P 25/28 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, A61P 35/00 (2006.01) C07F 9/6561 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61P 31/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US20 18/059004 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). 02 November 2018 (02. 11.2018) Declarations under Rule 4.17: (25) Filing Language: English — as to applicant's entitlement to apply for and be granted a (26) Publication Language: English patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the (30) Priority Data: earlier application (Rule 4.17(Hi)) 62/581,574 03 November 2017 (03. 11.2017) US 62/664,841 30 April 2018 (30.04.2018) US Published: — with international search report (Art.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • MMC International BV
    M.M.C. International Steroid Substances Steroid Test A Colour Steroid Test B Colour Steroid Test B Colour with UV Light Stanozolol/ Oxandrolone Test Clenbuterol/ Oxymetholone Test Ephedrine Test Alfadolone Orange Yellow Nil - - - Androsterone Orange Yellow White - - - Beclometasone Brown–yellow Orange Nil - - - Betamethasone Orange–brown Pink–Orange Nil - - - Boldenone Base (Equipoise, Ganabol) (pure powder) Warm red after 2 min. Dark Orange after 2 min. Bright Light Orange - - - Boldenone Undecanoate (oil) Dark brownish-red Dark Red Bright Light Orange - - - Boldenone Undecylenate (oil) Orange - Light Brown Dark Orange → Brown Bright Light Orange-Yellow - - - Carbenoxolone (CBX) Orange Yellow Yellow - - - Cholesterol Violet Orange White - - - Clenbuterol (Spiropent, Ventipulmin) - - - - Purple - Dark brown with yellow-green on the Dark brown with yellow-green on the Clomiphene (Androxal, Clomid, Omifin) Nil Dark brown to black No reaction Dark brown to black sides of the ampoule sides of the ampoule Cortisone Orange Yellow Green - - - Desoxycortone Blue–black Yellow Yellow - - - Dexamethasone Yellow Orange–pink Nil - - - Dienestrol Yellow Orange–red Nil - - - Diethylstilbestrol (DES) Orange (→yellow–green) Nil - - - Dimethisterone Brown–green Orange–red Yellow - - - Drostanolone Propionate (Masteron) (oil) Bright green Yellow-Orange Orange - - - Dydrogesterone (Duphaston) - Orange Green-Yellow - - - Enoxolone Orange Yellow Green-Yellow - - - Ephedrine (also for Pseudo- and Nor-Ephedrine) - - - - - Orange Estradiol (Oestradiol) Orange
    [Show full text]
  • International Journal of Orthopaedics
    International Journal of Orthopaedics Online Submissions: http://www.ghrnet.org/index./ijo/ Int Journal of Orthopaedics 2015 August 23 2(4): 347-352 doi:10.17554/j.issn.2311-5106.2015.02.89 ISSN 2311-5106 (Print), ISSN 2313-1462 (Online) ORIGINAL ARTICLE Contemporary Patterns of Anabolic Steroids Abuse and Associated Short Term Side Effects in Athletes Thomas A. Pagonis, Panagiotis P. Givissis Thomas A. Pagonis, Chelmsford Spinal Service, T&O Department, organism and the long term influence in a four years time interval. Broomfield MEHT, Chelmsford, the United Kingdom CONCLUSIONS: Contemporary AS users consistently practice Panagiotis P. Givissis, 1st Orthopaedic Clinic of Aristotles Univer- overdose polypharmacy. Knowledge of this type of abuse can be sity of Thessaloniki, G.U.H.G.Papanikolaou, Thessaloniki, Greece beneficial for the treatment of the side effects. Correspondence to: Thomas Pagonis MD, FRCS, PhD, Chelms- ford Spinal Service, T&O Department, Broomfield MEHT, Chelms- © 2015 ACT. All rights reserved. ford, the United Kingdom Email: [email protected] Key words: Anabolic steroids; Abuse; Anabolic steroid toxicity Telephone: +44 (0) 789 636 0517 Received: April 22, 2015 Revised: June 9, 2015 Pagonis TA, Givissis PP. Contemporary Patterns of Anabolic Accepted: June 13, 2015 Steroids Abuse and Associated Short Term Side Effects in Athletes. Published online: August 23, 2015 International Journal of Orthopaedics 2015; 2(4): 347-352 Available from: URL: http://www.ghrnet.org/index.php/ijo/article/view/3122 ABSTRACT INTRODUCTION: Anabolic steroids (AS) are synthetic derivatives INTRODUCTION of the testosterone molecule. In recent years, AS abuse by athletes Anabolic androgenic steroids (AAS) are synthetically manufactured of different levels has become more prevalent and circumspect.
    [Show full text]
  • TGA Review of Hgps
    A REVIEW TO UPDATE AUSTRALIA’S POSITION ON THE HUMAN SAFETY OF RESIDUES OF HORMONE GROWTH PROMOTANTS (HGPs) USED IN CATTLE Prepared by Chemical Review and International Harmonisation Section Office of Chemical Safety Therapeutic Goods Administration of the Department of Health and Ageing Canberra July 2003 A draft of this report was tabled at the 25th Meeting of the Advisory Committee on Pesticides and Health (ACPH), held in Canberra on the 1st May 2003. The report was subsequently endorsed out-of-session by the ACPH. Hormone Growth Promotants TABLE OF CONTENTS ABBREVIATIONS ................................................................................................................................................................4 EXECUTIVE SUMMARY ..................................................................................................................................................7 INTRODUCTION..................................................................................................................................................................9 HEALTH CONCERNS ASSOCIATED WITH HGP S................................................................................................................9 DIFFICULTIES ASSOCIAT ED WITH ASSESSING THE SAFETY OF HGPS.........................................................................10 RISK ASSESSMENTS OF HGP S .........................................................................................................................................10 PURPOSE OF THE CURRENT
    [Show full text]
  • LEGISLATIVE ASSEMBLY Question on Notice
    LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler Et Al
    US 20070078091A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0078091 A1 Hubler et al. (43) Pub. Date: Apr. 5, 2007 (54) PHARMACEUTICAL COMBINATIONS FOR (30) Foreign Application Priority Data COMPENSATING FORATESTOSTERONE DEFICIENCY IN MEN WHILE Sep. 6, 1998 (DE)..................................... 198 2.55918 SMULTANEOUSLY PROTECTING THE PROSTATE Publication Classification (76) Inventors: Doris Hubler, Schmieden (DE): (51) Int. Cl. Michael Oettel, Jena (DE); Lothar A6II 38/09 (2007.01) Sobek, Jena (DE); Walter Elger, Berlin A 6LX 3/57 (2007.01) (DE); Abdul-Abbas Al-Mudhaffar, A6II 3/56 (2006.01) Jena (DE) A 6LX 3/59 (2007.01) A 6LX 3/57 (2007.01) A61K 31/4709 (2007.01) Correspondence Address: A6II 3L/38 (2007.01) MILLEN, WHITE, ZELANO & BRANGAN, (52) U.S. Cl. ............................ 514/15: 514/171; 514/170; P.C. 514/651; 514/252.16; 514/252.17; 22OO CLARENDON BLVD. 514/3O8 SUTE 14OO ARLINGTON, VA 22201 (US) (57) ABSTRACT This invention relates to pharmaceutical combinations for (21) Appl. No.: 11/517,301 compensating for an absolute and relative testosterone defi ciency in men with simultaneous prophylaxis for the devel opment of a benign prostatic hyperplasia (BPH) or prostate (22) Filed: Sep. 8, 2006 cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a Related U.S. Application Data gestagen, an antigestagen, an antiestrogen, a GnRH analog. a testosterone-5C.-reductase inhibitor, an O-andreno-receptor (63) Continuation of application No. 09/719,221, filed on blocker or a phosphodiesterase inhibitor. In comparison to Feb. 16, 2001, filed as 371 of international application the combinations according to the invention, any active No.
    [Show full text]
  • BCBSM Clinical Drug List (Formulary)
    Blue Cross Blue Shield of Michigan ® ® Clinical Drug List (Formulary) Please note that this listing of medications contained in this Blue Cross Blue Shield of Michigan Clinical Drug List (Formulary) is current at the time that the list is posted to this website, and is subject to change. INTRODUCTION Blue Cross Blue Shield of Michigan is pleased to provide the Clinical Drug List as a useful reference and educational tool to assist providers in selecting cost-effective therapies. Please familiarize yourself with this information. To provide effective high-quality care, this Clinical Drug List requires the continuing support of physicians and phar - macists. Your questions and suggestions are welcome. PREFACE The Blue Cross Blue Shield of Michigan Clinical Drug List is a list of FDA-approved prescription drug medications reviewed by the BCBSM/BCN Pharmacy and Therapeutics (P&T) Committee. The Clinical Drug List will assist in maintaining the quality of patient care and containing cost for the member’s drug benefit plan. Providers, physicians, and pharmacists are encouraged to refer to the Clinical Drug List when selecting prescription drug therapy for eligible plan members. Physicians are encouraged to prescribe med ications included in the Clinical Drug List whenever possible. If a prescrip tion is written for a nonpreferred drug or for a drug or dose not recommended for use in the elderly or pregnant, phar macists are encouraged to contact the physician. The benefit plan administrator will monitor provider- specific drug list prescribing and communicate with providers to optimize compliance. The Clinical Drug List is divided into major therapeutic categories (chapters) for easy use.
    [Show full text]
  • Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS
    Chapter 246-883 Chapter 246-883 WAC PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS WAC Authority: 1979 1st ex. s. c 139. 79-09-138 (Order 149, Resolution No. 246-883-020 Identification of legend drugs for purposes of chapter 9/79), § 360-32-050, filed 9/5/79.] 69.41 RCW. 246-883-025 Introductory trade or stock packages. 246-883-030 Ephedrine prescription restrictions. WAC246-883-025 246-883-025 Introductory trade or stock pack- 246-883-040 Regulated steroids. 246-883-050 Theophylline prescription restrictions. ages. Introductory trade or stock packages may be distributed by registered drug manufacturers to licensed pharmacies 246-883-020 under the following conditions: WAC 246-883-020 Identification of legend drugs for purposes of chapter 69.41 RCW. (1) In accordance with (1) The package shall be invoiced by the drug manufac- chapter 69.41 RCW, the board of pharmacy finds that those turer as a no charge sale. drugs which have been determined by the Food and Drug (2) The product shall be distributed by the manufacturer Administration, under the Federal Food, Drug and Cosmetic to the pharmacy by mail or common carrier. Act, to require a prescription under federal law should also be (3) The drug's package shall not be marked as a sample classified as legend drugs under state law because of their or with any other labeling that is inconsistent with the claim toxicity or potential for harmful effect, the methods of their that the manufacturer intended the package for sale. use and the collateral safeguards necessary to their use, indi- (4) The manufacturer shall be limited to distributing one cate that they are only safe for use under the supervision of a introductory package of each dosage strength of a product on practitioner.
    [Show full text]